Stock data
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX) reported net income of -US$20.16M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$18.71M | -US$20.16M | — |
| 2024 | — | — | -US$20.35M | -US$20.41M | — |
| 2023 | US$0.06M | — | -US$22.25M | -US$22.27M | — |
| 2022 | US$0.13M | — | -US$17.78M | -US$17.59M | — |
| 2021 | US$0.13M | — | -US$13.83M | -US$13.89M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$4.68M | — |
| 2026-03-31 | — | -US$5.61M | — |
| 2025-12-31 | — | -US$4.54M | — |
| 2025-09-30 | — | -US$5.28M | — |
| 2025-06-30 | — | -US$5.81M | — |
| 2025-03-31 | — | -US$4.53M | — |
| 2024-12-31 | — | -US$3.77M | — |
| 2024-09-30 | — | -US$4.49M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.